Immunotherapeutic composition for the treatment of cancer by inducing allogenic rejection employing fusion proteins comprising an MHC class 1 HLA amino acid sequence mismatched to the host

The present invention provides compositions and methods for inducing allogenic tumor rejection and, more particularly, but not exclusively, compositions and methods employing fusion proteins comprising an MHC class 1 HLA amino acid sequence mismatched to the host. According to an aspect of some embodiments of the present invention there is provided a method of killing a tumor cell presenting a tumor antigen, the method comprising administering to an individual a composition-of-matter comprising at least one fusion protein comprising a viral MHC-restricted peptide; a human beta-2-microglobulin; an alpha chain of a human MHC class I mol. and a binding domain of an antibody which specifically binds to the tumor antigen, wherein the alpha chain of a human MHC mol. is allogeneic to the individual, so as to elicit an alloimmune response to the tumor cell presenting the antigen, thereby killing the tumor cell.